Literature DB >> 1887863

Inhibition of vein graft intimal proliferative lesions in the rat by heparin.

G M Hirsch1, M J Karnovsky.   

Abstract

The authors investigated the effect of heparin on the development of myointimal proliferative lesions in a rat vein graft model. Intimal thickening in this model was most pronounced in the anastomotic regions, and was composed principally of vascular smooth muscle cells, as identified by immunocytochemistry with anti-muscle actin antibody, HHF-35. Medial thickening was less cellular, and evenly distributed throughout the grafts. Continuous, intravenous infusion of whole heparin at 0.3 mg/kg/hr effectively inhibited the development of myointimal proliferative lesions, although with no effect on medial thickening. The authors suggest that heparin, through its antiproliferative activity for vascular smooth muscle cells, may have a potentially important pharmacologic role in preventing vein graft failure, which most commonly results from the development of myointimal proliferative lesions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1887863      PMCID: PMC1886235     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  22 in total

1.  Effect of compliance mismatch on vascular graft patency.

Authors:  W M Abbott; J Megerman; J E Hasson; G L'Italien; D F Warnock
Journal:  J Vasc Surg       Date:  1987-02       Impact factor: 4.268

Review 2.  Regulation of vascular smooth muscle cell growth by heparin and heparan sulfates.

Authors:  J J Castellot; T C Wright; M J Karnovsky
Journal:  Semin Thromb Hemost       Date:  1987-10       Impact factor: 4.180

3.  Thoracic surgery manpower: the fourth manpower study of thoracic surgery: 1985 report of the Ad Hoc Committee on Manpower of The American Association for Thoracic Surgery and The Society of Thoracic Surgeons.

Authors:  F D Loop; B R Wilcox; J N Cunningham; R G Fosburg; A S Geha; H Laks; J B Mark; K Badhwar; G W Williams
Journal:  Ann Thorac Surg       Date:  1987-11       Impact factor: 4.330

4.  Vascular surgery in the United States. Report of the Joint Society for Vascular Surgery--International Society for Cardiovascular Surgery Committee on Vascular Surgical Manpower.

Authors:  C B Ernst; I M Rutkow; R J Cleveland; J R Folse; G Johnson; J C Stanley
Journal:  J Vasc Surg       Date:  1987-12       Impact factor: 4.268

5.  Pathologic changes in aortic-coronary arterial saphenous vein grafts.

Authors:  Z Vlodaver; J E Edwards
Journal:  Circulation       Date:  1971-10       Impact factor: 29.690

6.  Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin.

Authors:  A W Clowes; M M Clowes
Journal:  Lab Invest       Date:  1985-06       Impact factor: 5.662

7.  Kinetics of vein graft hyperplasia: association with tangential stress.

Authors:  R M Zwolak; M C Adams; A W Clowes
Journal:  J Vasc Surg       Date:  1987-01       Impact factor: 4.268

8.  Morphologic changes in long-term saphenous vein bypass grafts.

Authors:  J B Atkinson; M B Forman; W K Vaughn; M Robinowitz; H A McAllister; R Virmani
Journal:  Chest       Date:  1985-09       Impact factor: 9.410

9.  Effect of heparin on adaptation of vein grafts to arterial circulation.

Authors:  T R Kohler; T Kirkman; A W Clowes
Journal:  Arteriosclerosis       Date:  1989 Jul-Aug

10.  Heparin and glomerular epithelial cell-secreted heparin-like species inhibit mesangial-cell proliferation.

Authors:  J J Castellot; R L Hoover; P A Harper; M J Karnovsky
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

View more
  2 in total

Review 1.  Rationale and practical techniques for mouse models of early vein graft adaptations.

Authors:  Peng Yu; Binh T Nguyen; Ming Tao; Christina Campagna; C Keith Ozaki
Journal:  J Vasc Surg       Date:  2010-06-22       Impact factor: 4.268

2.  Effect of heparin on antigen-induced airway responses and pulmonary leukocyte accumulation in neonatally immunized rabbits.

Authors:  J M Preuss; C P Page
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.